Clinical Trial: A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07820085) titled 'A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)' on Aug. 25.

Brief Summary: PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP.

The study has three parts:

Part 1: Phase 2b

* Find the right dose of PORT-77 to lower PPIX levels in the blood

* Test if PORT-77 lowers PPIX levels better than placebo

* Check the safety of each dose

Part 2: Phase 3

* Test if PORT-77 lowers PPIX levels better than placebo

* Test if PORT-77 increases the amount of time...